Clinical Trial Goal
To find out:
- The highest dose of HH2853 that’s safe to give
- If HH2853 is safe and works well to treat DLBCL, follicular lymphoma or PTCL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have 1 of the following diseases that has relapsed or is refractory:
- DLBCL
- Follicular lymphoma
- PTCL
- Do not have untreated cancer cells in your brain or spinal cord
- Have not had a blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
HH2853 is a drug that blocks EZH1 and EZH2 in certain cells.
You’ll get:
- HH2853 – A pill that you take by mouth 2 times every day. The dose you’ll get depends on when you start the trial and how safe it’s been.
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You’ll have biopsies and scans to see how well the treatment is working. The clinical trial doctors will check your health for as long as you’re in the trial.
The Food and Drug Administration (FDA) has not yet approved HH2853.
Locations
Mayo ClinicCOMPLETED
Phoenix, Arizona
Mayo ClinicCOMPLETED
Jacksonville, Florida
Mayo ClinicCOMPLETED
Rochester, Minnesota
NEXT OncologyCOMPLETED
San Antonio, Texas
Sponsors
lead: Haihe Biopharma Co., Ltd.
